CureVac AG

CureVac AG

CureVac AG

Date Founded



Paul-Ehrlich-Straße 15,Tübingen, Baden Wuerttemberg 72076

Type of Company



Holding Companies

Company Description

CureVac AG develops tumor immunotherapy. It offers RNA optimization, RNActive, RNArt, RNAdjuvant, in house GMP production, research and development services, and PureMessenger applications. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany.

Executives & Employees

Chairman of the Executive Board & Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Technology Officer

Chief Development Officer

Chief Medical Officer

Chief Scientific Officer

Vice President-Preclinical

Vice President, Business Development

Board of Directors

Director at CureVac AG

Co-Founder at Wipfler & Partner

Paths to CureVac AG
Potential Connections via
Relationship Science
CureVac AG
Advisors & Consultants

Account Director at Brunswick Group LLP


Vice President at Tiberend Strategic Advisors, Inc.

Details Hidden

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Details Hidden

LBBW-AMI uses a combination of active and passive approaches to invest across asset classes. They invest globally with a focus on European equities. The firm's index-oriented investment approach follows equities in various indexes and focuses on larger companies in sectors such as information technology, health care and energy, as well as on German small- and mid-caps. They use a top-down approach to identify both short-term cycles and long-term structural changes. LBBW-AMI employs a combination of fundamental quantitative and fundamental qualitative processes. They base fundamental qualitative investments on buy-side research which leverages their parent bank's network. They manage risk quantitatively ex-ante and ex-post using mathematical models such as Value-at-Risk and Tracking Error.

Details Hidden
Arcturus Therapeutics Ltd. Pharmaceuticals | San Diego, CA

Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CureVac AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CureVac AG's profile does not indicate a business or promotional relationship of any kind between RelSci and CureVac AG.